Immunological evaluation demonstrated that like semisynthetic glycoprotein vaccine 5/Al, all our synthetic conjugates could effectively induce strong and consistent T cell-dependent immunity with switching from IgM to IgG in mice, as is desirable for therapeutic cancer vaccines. This evidence concerns the gene CD40LG and cancer.